The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality

[1]  Nicolai J. Birkbak,et al.  Lung adenocarcinoma promotion by air pollutants , 2023, Nature.

[2]  Stephen V. Liu,et al.  NSCLC With Synchronous EGFR Mutations in Li Fraumeni Syndrome: A Case Report , 2023, JTO clinical and research reports.

[3]  J. Onuchic,et al.  BAP1 is a novel regulator of HIF-1α , 2023, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Villani,et al.  Germline variants associated with toxicity to immune checkpoint blockade , 2022, Nature Medicine.

[5]  M. Berger,et al.  Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Schäffer,et al.  Characterization of Oncology Clinical Trials Using Germline Genetic Data , 2022, JAMA network open.

[7]  R. Nussbaum,et al.  Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer , 2022, JCO precision oncology.

[8]  Yan Zhang,et al.  Mutational landscape of homologous recombination‐related genes in small‐cell lung cancer , 2022, Cancer medicine.

[9]  R. Nussbaum,et al.  Landscape of pathogenic germline variants in patients with lung cancer. , 2022, Journal of Clinical Oncology.

[10]  D. Fennell,et al.  Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial , 2022, EClinicalMedicine.

[11]  C. von Kalle,et al.  Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  B. Besse,et al.  Radon and Lung Cancer: Current Trends and Future Perspectives , 2022, Cancers.

[13]  T. Skorski,et al.  Synthetic Lethality Targeting Polθ , 2022, Genes.

[14]  C. Allegra,et al.  Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms. , 2022, Journal of Clinical Oncology.

[15]  N. Viñolas,et al.  Prevalence of incidental pathogenic germline variants detected in cfDNA in patients with oncogene-driven non-small cell lung cancer. , 2022, Journal of Clinical Oncology.

[16]  D. Gerber,et al.  Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report , 2022, JTO clinical and research reports.

[17]  J. Henson.  Paired Tumor-Germline Testing as a Driver in Better Cancer Care. , 2022, JAMA network open.

[18]  J. Garber,et al.  Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines , 2022, JAMA network open.

[19]  M. Zauderer,et al.  EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. , 2022, The Lancet. Oncology.

[20]  B. Taylor,et al.  Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. , 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  Y. C. Lee,et al.  BAP1 loss by immunohistochemistry predicts improved survival to first line platinum/pemetrexed chemotherapy for pleural mesothelioma patients: A validation study. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Y. Kamatani,et al.  Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants , 2022, JAMA oncology.

[23]  C. Swanton,et al.  The translational challenges of precision oncology. , 2022, Cancer cell.

[24]  E. Jonasch,et al.  Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. , 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[25]  Chuong D. Hoang,et al.  Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  P. Jänne,et al.  Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  M. Tainsky,et al.  Functional analysis of ATM variants in a high risk cohort provides insight into missing heritability. , 2022, Cancer genetics.

[28]  Rebecca D. Kehm,et al.  DNA repair phenotype and cancer risk: a systematic review and meta-analysis of 55 case–control studies , 2022, Scientific Reports.

[29]  Alicia R. Martin,et al.  Diversity in Genomic Studies: A Roadmap to Address the Imbalance , 2022, Nature Medicine.

[30]  Edel del Barco Morillo,et al.  Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis , 2022, Biomedicines.

[31]  G. Scagliotti,et al.  Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. , 2022, European journal of cancer.

[32]  M. Ladanyi,et al.  Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Jun Liu,et al.  Genomic features of Chinese small cell lung cancer , 2021, BMC medical genomics.

[34]  L. Madlensky,et al.  Disparities in germline testing among racial minorities with prostate cancer , 2021, Prostate Cancer and Prostatic Diseases.

[35]  F. Coulet,et al.  Lung cancer is also a hereditary disease , 2021, European Respiratory Review.

[36]  R. Wilson,et al.  Genomic Profiling of Lung Adenocarcinoma in Never-Smokers , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Steinberg,et al.  Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene , 2021, JTO clinical and research reports.

[38]  E. Kazerooni,et al.  Screening for lung cancer in individuals who never smoked: An IASLC Early Detection and Screening Committee Report. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  R. Govindan,et al.  Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  H. Wakelee,et al.  Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females. , 2021, Journal of the National Cancer Institute.

[41]  P. Zhao,et al.  Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017 , 2021, JAMA network open.

[42]  L. Sequist,et al.  Lung cancer , 2021, The Lancet.

[43]  N. Agarwal,et al.  Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer , 2021, JCO precision oncology.

[44]  M. Mansournia,et al.  Burden of tracheal, bronchus and lung cancer and its attributable risk factors in 204 countries and territories, 1990-2019. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  S. Steinberg,et al.  Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies , 2021, Science Translational Medicine.

[46]  C. Richards,et al.  Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. , 2021, The Lancet. Respiratory medicine.

[47]  L. Schwartz,et al.  Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. , 2021, Clinical Lung Cancer.

[48]  Tongchao Zhang,et al.  Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis. , 2020, Lung cancer.

[49]  S. Pastorino,et al.  Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma , 2020, Proceedings of the National Academy of Sciences.

[50]  R. Nussbaum,et al.  Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. , 2020, JAMA oncology.

[51]  Jaana M. Hartikainen,et al.  Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. , 2021, The New England journal of medicine.

[52]  A. Balmain.  The critical roles of somatic mutations and environmental tumor-promoting agents in cancer risk , 2020, Nature Genetics.

[53]  J. Bosch-Barrera,et al.  Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). , 2020, Lung cancer.

[54]  S. Shah,et al.  ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Zhao-quan Shi,et al.  Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation. , 2020, Lung cancer.

[56]  S. Tamiya,et al.  Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years , 2020, Pathology international.

[57]  R. Jensen,et al.  Large‐scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma , 2020, The Journal of pathology.

[58]  A. Gonzalez-Perez,et al.  A compendium of mutational cancer driver genes , 2020, Nature Reviews Cancer.

[59]  G. Scagliotti,et al.  A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. , 2020, Clinical lung cancer.

[60]  J. Brugarolas,et al.  Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. , 2020, Cancer discovery.

[61]  O. Røe,et al.  Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review , 2020, International journal of molecular sciences.

[62]  S. Arron,et al.  Tumour predisposition and cancer syndromes as models to study gene–environment interactions , 2020, Nature Reviews Cancer.

[63]  M. S. Artigas,et al.  Protein-altering germline mutations implicate novel genes related to lung cancer development , 2020, Nature Communications.

[64]  J. Gregg,et al.  Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity , 2020, JCO precision oncology.

[65]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[66]  F. Galateau-Sallé,et al.  Malignant Mesothelioma In Situ: Clinical and Pathologic Implications. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[67]  M. Zauderer,et al.  Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk , 2020, medRxiv.

[68]  C. Lázaro,et al.  Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[69]  E. Clayton,et al.  Key Expert Stakeholder Perceptions of the Law of Genomics: Identified Problems and Potential Solutions , 2020, Journal of Law, Medicine & Ethics.

[70]  T. Nakajima,et al.  Long-Lasting Response to Nivolumab for a Patient With Lynch Syndrome-Associated Lung Adenocarcinoma. , 2020, JCO precision oncology.

[71]  Jefree J. Schulte,et al.  Application of immunohistochemistry in diagnosis and management of malignant mesothelioma , 2020, Translational lung cancer research.

[72]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Ladanyi,et al.  Brief Report: Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[74]  D. Carraro,et al.  High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant. , 2019, Clinical lung cancer.

[75]  Guo-hang Ma,et al.  Spectrum of Pathogenic Germline Mutations in Chinese Lung Cancer Patients through Next-Generation Sequencing , 2019, Pathology & Oncology Research.

[76]  Y. Guan,et al.  P2.04-54 Characteristic of MSI-H Lung Cancer Patients Identified with Targeted Next-Generation Sequencing , 2019, Journal of Thoracic Oncology.

[77]  C. Lázaro,et al.  P1.01-54 Somatic Genome Alterations in Lung Cancer Patients Diagnosed with Li Fraumeni Syndrome , 2019, Journal of Thoracic Oncology.

[78]  F. Galateau-Sallé,et al.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy , 2019, CA: a cancer journal for clinicians.

[79]  F. Galateau-Sallé,et al.  Malignant mesothelioma in situ: morphologic features and clinical outcome , 2019, Modern Pathology.

[80]  Chengping Hu,et al.  Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients , 2019, Cancer biology & medicine.

[81]  N. Socci,et al.  Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.

[82]  G. Matullo,et al.  Genetic predisposition for malignant mesothelioma: A concise review. , 2019, Mutation research.

[83]  Tong-fu Yu,et al.  Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study , 2019, Front. Oncol..

[84]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[85]  Tianhui Chen,et al.  High Time for Complete Ban on Asbestos Use in Developing Countries. , 2019, JAMA oncology.

[86]  Stephanie A Cohen,et al.  Genetic Counseling and Testing in a Community Setting: Quality, Access, and Efficiency. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[87]  Jae Woo Choi,et al.  Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. , 2019, Lung cancer.

[88]  Yuan Qi,et al.  Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. , 2019, JCO precision oncology.

[89]  T. Walsh,et al.  Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy , 2019, Proceedings of the National Academy of Sciences.

[90]  Ahmet Zehir,et al.  Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Ivana K. Kim,et al.  Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide , 2018, Journal of the National Cancer Institute.

[92]  S. Pastorino,et al.  A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[94]  G. Sonpavde,et al.  Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  G. Scagliotti,et al.  Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes , 2018, Genes, chromosomes & cancer.

[96]  J. Onuchic,et al.  Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine , 2018, Cell Death & Differentiation.

[97]  Xue Wu,et al.  EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[98]  A. Uitterlinden,et al.  Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin , 2018, Journal of the National Cancer Institute.

[99]  Lauren L. Ritterhouse,et al.  Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  J. Aerts,et al.  Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma , 2018, JCO precision oncology.

[101]  S. Lam,et al.  Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners , 2018, International Archives of Occupational and Environmental Health.

[102]  W. Hahn,et al.  Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer , 2018, Genetics in Medicine.

[103]  Yibo Gao,et al.  Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. , 2018, Cancer letters.

[104]  F. Galateau-Sallé,et al.  Malignant Mesothelioma and Its Non-Asbestos Causes. , 2018, Archives of pathology & laboratory medicine.

[105]  R. Klein,et al.  Rare, Pathogenic Germline Variants in Fanconi Anemia Genes Increase Risk for Squamous Lung Cancer , 2018, Clinical Cancer Research.

[106]  T. Frebourg,et al.  Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial , 2017, JAMA oncology.

[107]  S. E. Stanley,et al.  Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[108]  J. Garber,et al.  OA 06.02 Final Report of the INHERIT EGFR Study - 33 Unrelated Kindreds Carrying Germline EGFR Mutations , 2017 .

[109]  G. Matullo,et al.  Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. , 2017, Cancer letters.

[110]  C. Paweletz,et al.  Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients , 2017, Clinical Cancer Research.

[111]  P. Kantoff,et al.  Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.

[112]  Kenji Suzuki,et al.  DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. , 2017, Lung cancer.

[113]  R. Hromas,et al.  Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition , 2017, Cancer Chemotherapy and Pharmacology.

[114]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[115]  D. Schrump,et al.  Targeting the epigenome in malignant pleural mesothelioma. , 2017, Translational lung cancer research.

[116]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[117]  David C. Smith,et al.  Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. , 2017, Cancer discovery.

[118]  Ruedi Aebersold,et al.  A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability , 2017, Cell.

[119]  Mark E. Robson,et al.  Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. , 2017, JCO precision oncology.

[120]  G. Sica,et al.  Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  S. Milchgrub,et al.  Metachronous Uterine Endometrioid Adenocarcinoma and Peritoneal Mesothelioma in Lynch Syndrome: A Case Report , 2017, International journal of surgical pathology.

[122]  S. Emri.  The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad. , 2017, Annals of translational medicine.

[123]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[124]  Jay Shendure,et al.  Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.

[125]  G. Matullo,et al.  CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. , 2016, Cancer letters.

[126]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[127]  S. Pastorino,et al.  Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma , 2016, Oncogene.

[128]  R. Houlston,et al.  Quantifying the heritability of testicular germ cell tumour using both population-based and genomic approaches , 2015, Scientific Reports.

[129]  S. Armstrong,et al.  Loss of BAP1 function leads to EZH2-dependent transformation , 2015, Nature Medicine.

[130]  R. McCormack,et al.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). , 2015, American journal of cancer research.

[131]  D. Ferrante,et al.  Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment , 2015, Occupational and Environmental Medicine.

[132]  S. Pastorino,et al.  BAP1 hereditary cancer predisposition syndrome: a case report and review of literature , 2015, Biomarker Research.

[133]  M. Becich,et al.  High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[134]  Christopher D. Heinen,et al.  Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.

[135]  A. Richardson,et al.  BRCA1 haploinsufficiency for replication stress suppression in primary cells , 2014, Nature Communications.

[136]  Eun‐Kee Park,et al.  Asbestos: use, bans and disease burden in Europe , 2014, Bulletin of the World Health Organization.

[137]  T. Morii,et al.  V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[138]  A. Ruano-Raviña,et al.  Genetic Susceptibility, Residential Radon, and Lung Cancer in a Radon Prone Area , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[139]  O. Dekkers,et al.  Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. , 2014, The Journal of clinical endocrinology and metabolism.

[140]  F. Forastiere,et al.  Familial malignant mesothelioma: a population-based study in central Italy (1980-2012). , 2014, Cancer epidemiology.

[141]  M. Ladanyi,et al.  Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[142]  William Wheeler,et al.  Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer , 2014, Nature Genetics.

[143]  Jessica K. Gagnon,et al.  Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. , 2014, Molecular cell.

[144]  David M. Thomas,et al.  Li-Fraumeni syndrome: cancer risk assessment and clinical management , 2014, Nature Reviews Clinical Oncology.

[145]  J. Soh,et al.  Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[146]  A. Curnow,et al.  The Cellular and Molecular Carcinogenic Effects of Radon Exposure: A Review , 2013, International journal of molecular sciences.

[147]  M. Carbone,et al.  Asbestos is not just asbestos: an unrecognised health hazard. , 2013, The Lancet. Oncology.

[148]  Laura S Welch,et al.  The worldwide pandemic of asbestos-related diseases. , 2013, Annual review of public health.

[149]  Thomas Krausz,et al.  BAP1 and cancer , 2013, Nature Reviews Cancer.

[150]  C. Sempoux,et al.  Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. , 2012, Human pathology.

[151]  Ronglai Shen,et al.  Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers , 2012, Clinical Cancer Research.

[152]  Benjamin M. Robinson,et al.  Malignant pleural mesothelioma: an epidemiological perspective. , 2012, Annals of cardiothoracic surgery.

[153]  J. Bilezikian,et al.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.

[154]  H. Pass,et al.  BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs , 2012, Journal of Translational Medicine.

[155]  M. Ladanyi,et al.  Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[156]  L. Cerroni,et al.  A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression , 2012, The American journal of surgical pathology.

[157]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  F. Liu,et al.  Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy , 2011, Clinical Cancer Research.

[159]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[160]  H. Pass,et al.  Erionite exposure in North Dakota and Turkish villages with mesothelioma , 2011, Proceedings of the National Academy of Sciences.

[161]  M. Ladanyi,et al.  New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer , 2011, Clinical Cancer Research.

[162]  J. Shih,et al.  Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[163]  Y. Morishita,et al.  Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  G. Cesana,et al.  Mesothelioma and asbestos, fifty years of evidence: Chris Wagner and the contribution of the Italian occupational medicine community. , 2010, La Medicina del lavoro.

[165]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  S. Ou,et al.  Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[167]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[168]  M. Musti,et al.  Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature. , 2007, American journal of industrial medicine.

[169]  H. Pass,et al.  A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes , 2007, Nature Reviews Cancer.

[170]  D. Camidge,et al.  Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data , 2006, British Journal of Cancer.

[171]  H. Koong,et al.  Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  A. Musk,et al.  Malignant mesothelioma , 2005, The Lancet.

[173]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[174]  J. Burgess,et al.  Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1 , 2005, Cancer.

[175]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  Christopher I. Amos,et al.  Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk , 2003, Human Genetics.

[177]  J. Varley,et al.  Relative frequency and morphology of cancers in carriers of germline TP53 mutations , 2001, Oncogene.

[178]  M. Tucker,et al.  Hereditary retinoblastoma and risk of lung cancer. , 2000, Journal of the National Cancer Institute.

[179]  M. Spitz,et al.  Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. , 2000, Journal of the National Cancer Institute.

[180]  J. Willey,et al.  Cytogenetic and molecular genetic analysis of tumorigenic human bronchial epithelial cells induced by radon alpha particles. , 1997, Carcinogenesis.

[181]  B. Lanphear,et al.  Latent period for malignant mesothelioma of occupational origin. , 1992, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[182]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[183]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[184]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[185]  L. Billingham,et al.  P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC: Topic: Drug Treatment Alone and in Combination with Radiotherapy , 2017 .

[186]  H. Wakelee,et al.  Lung Cancer in Never Smokers. , 2016, Advances in experimental medicine and biology.

[187]  H. Pass,et al.  Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. , 2015, Carcinogenesis.

[188]  V. Torri,et al.  Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. , 2013, Cancer Treatment Reviews.

[189]  K. Hemminki,et al.  Mesothelioma incidence seems to have leveled off in Sweden , 2003, International journal of cancer.

[190]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.